# Humacyte (HUMA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/HUMA
## Company Profile
- Ticker: HUMA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.665 USD
- Market cap: 308606560.12 USD
- Last updated: 2026-08-12
## Business Overview
### Bioengineered Human Tissue Platform
Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale.
### SYMVESS
SYMVESS is an FDA-approved acellular tissue-engineered vessel for urgent arterial repair after extremity vascular trauma. It is Humacyte's first commercial product and validates the broader tissue platform.
### Hemodialysis Access
The Phase 3 V012 study compared the vessel with autologous arteriovenous fistulas for hemodialysis access in women. Positive results form the basis for a planned supplemental BLA.
### Coronary Program
Humacyte's coronary tissue-engineered vessel is being developed as an off-the-shelf conduit for coronary artery bypass grafting. The FDA has cleared the IND for a first-in-human Phase 2a study.
### Broader Vascular Applications
Additional development areas include peripheral artery disease, pediatric heart surgery, type 1 diabetes, and other cell and tissue applications.
## Why The Stock Is Moving

Following the latest company update, “Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update”, HUMA closed down 6.34% at $0.6650 on Aug 12, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Initiation of a Phase 2a study of the coronary tissue-engineered vessel in coronary artery bypass grafting in the third quarter of 2026.
- Submission of a supplemental BLA for the acellular tissue-engineered vessel in hemodialysis access in the second half of 2026.

## Recent News
- 2026-08-12 11:00 EST — [Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/HUMA/humacyte-announces-second-quarter-2026-financial-results-and-provides-business-u-5b5951e6) — Source: Humacyte
- 2026-08-07 12:00 EST — [Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026](https://biopharmsignal.com/news/HUMA/humacyte-to-announce-2026-second-quarter-financial-results-and-provide-business--20c7f207) — Source: Humacyte
- 2026-07-27 12:00 EST — [Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting](https://biopharmsignal.com/news/HUMA/humacyte-announces-fda-acceptance-of-ind-for-first-in-human-clinical-study-of-ct-0d8bc87b) — Source: Humacyte
- 2026-07-14 12:00 EST — [Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access](https://biopharmsignal.com/news/HUMA/humacyte-appoints-key-nephrologists-as-advisors-to-prepare-for-planned-commercia-5778fa4b) — Source: Humacyte
- 2026-06-15 12:00 EST — [Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting](https://biopharmsignal.com/news/HUMA/humacyte-s-bioengineered-blood-vessel-outperforms-the-standard-of-care-for-women-b5163c36) — Source: Humacyte